Markus Warmuth made CEO at Eisai spin-out H3
This article was originally published in Scrip
Executive Summary
H3 Biomedicine, a wholly owned subsidiary of Eisai focusing on oncology drug discovery, has appointed Dr Markus Warmuth CEO. Dr Warmuth joined H3 in August 2011 as chief scientific officer, and previously served as head of oncology drug discovery for the Novartis Institute for Biomedical Research.